292 related articles for article (PubMed ID: 26016715)
1. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ
Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715
[TBL] [Abstract][Full Text] [Related]
2. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.
Canet MJ; Hardwick RN; Lake AD; Dzierlenga AL; Clarke JD; Goedken MJ; Cherrington NJ
Drug Metab Dispos; 2015 Feb; 43(2):266-72. PubMed ID: 25488932
[TBL] [Abstract][Full Text] [Related]
3. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.
Canet MJ; Hardwick RN; Lake AD; Dzierlenga AL; Clarke JD; Cherrington NJ
Drug Metab Dispos; 2014 Apr; 42(4):586-95. PubMed ID: 24384915
[TBL] [Abstract][Full Text] [Related]
4. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
Higgins JW; Bedwell DW; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2012 Jun; 40(6):1170-7. PubMed ID: 22407892
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice.
Jang EH; Kim HK; Park CS; Kang JH
Drug Metab Pharmacokinet; 2010; 25(4):392-7. PubMed ID: 20814161
[TBL] [Abstract][Full Text] [Related]
6. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
7. Epigallocatechin gallate attenuated non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet.
Ding Y; Sun X; Chen Y; Deng Y; Qian K
Eur J Pharmacol; 2015 Aug; 761():405-12. PubMed ID: 25967348
[TBL] [Abstract][Full Text] [Related]
8. Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1.
Li L; Lei H; Wang W; Du W; Yuan J; Tu M; Zhou H; Zeng S; Jiang H
Biopharm Drug Dispos; 2018 Nov; 39(9):411-419. PubMed ID: 30294927
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.
Katsura A; Morishita A; Iwama H; Tani J; Sakamoto T; Tatsuta M; Toyota Y; Fujita K; Kato K; Maeda E; Nomura T; Miyoshi H; Yoneyama H; Himoto T; Fujiwara S; Kobara H; Mori H; Niki T; Ono M; Hirashima M; Masaki T
Int J Mol Med; 2015 Apr; 35(4):877-84. PubMed ID: 25672270
[TBL] [Abstract][Full Text] [Related]
10. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J
Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068
[TBL] [Abstract][Full Text] [Related]
11. Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies.
Zhang G; Ma Y; Xi D; Rao Z; Sun X; Wu X
Biopharm Drug Dispos; 2019 Jan; 40(1):3-11. PubMed ID: 30488476
[TBL] [Abstract][Full Text] [Related]
12. Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease.
Sundelin EIO; Gormsen LC; Heebøll S; Vendelbo MH; Jakobsen S; Munk OL; Feddersen S; Brøsen K; Hamilton-Dutoit SJ; Pedersen SB; Grønbaek H; Jessen N
Br J Clin Pharmacol; 2019 Aug; 85(8):1761-1770. PubMed ID: 30973968
[TBL] [Abstract][Full Text] [Related]
13. Role of ADAMTS13 in diet-induced liver steatosis.
Geys L; Roose E; Vanhoorelbeke K; Bedossa P; Scroyen I; Lijnen HR
Mol Med Rep; 2017 Aug; 16(2):1451-1458. PubMed ID: 29067443
[TBL] [Abstract][Full Text] [Related]
14. Gene-by-Environment Interaction of Bcrp
Toth EL; Li H; Dzierlenga AL; Clarke JD; Vildhede A; Goedken M; Cherrington NJ
Drug Metab Dispos; 2018 Nov; 46(11):1478-1486. PubMed ID: 30166404
[TBL] [Abstract][Full Text] [Related]
15. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.
Sahai A; Malladi P; Pan X; Paul R; Melin-Aldana H; Green RM; Whitington PF
Am J Physiol Gastrointest Liver Physiol; 2004 Nov; 287(5):G1035-43. PubMed ID: 15256362
[TBL] [Abstract][Full Text] [Related]
16. Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance.
Toth EL; Clarke JD; Csanaky IL; Cherrington NJ
Biochem Pharmacol; 2020 Apr; 174():113780. PubMed ID: 31881192
[TBL] [Abstract][Full Text] [Related]
17. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.
Cho SK; Yoon JS; Lee MG; Lee DH; Lim LA; Park K; Park MS; Chung JY
Clin Pharmacol Ther; 2011 Mar; 89(3):416-21. PubMed ID: 21270793
[TBL] [Abstract][Full Text] [Related]
18. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
19. Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice.
Kammoun HL; Allen TL; Henstridge DC; Kraakman MJ; Peijs L; Rose-John S; Febbraio MA
PLoS One; 2017; 12(6):e0179099. PubMed ID: 28632778
[TBL] [Abstract][Full Text] [Related]
20. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
